Lacutamab is under investigation in clinical trial NCT02593045 (Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.